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Objective. The aim was to evaluate the expression of matrix metalloproteinases (MMPs) 7 and 26 in ameloblastomas
and adenomatoid odontogenic tumors (AOTs).
Study design. Twenty intraosseous solid ameloblastomas and 10 intraosseous AOTs were evaluated regarding
immunohistochemical expression of MMP-7 and -26 in the epithelium and stroma.
Results. There was no statistically significant difference in MMP-7 and -26 expression between the epithelium of
ameloblastomas (P  .50) and AOTs (P  .90). Stromal staining for MMP-7 was evident in all cases. For MMP-26,
stromal staining was observed in 65% of ameloblastomas and 50% of AOTs, and this difference was not statistically
significant (P  .69).
Conclusion. The marked expression of these matrilysins suggests their role in the process of tissue remodeling and
growth in the studied tumors, but it does not relate to the their distinct patterns of aggressiveness. (Oral Surg Oral
Med Oral Pathol Oral Radiol Endod 2009;108:417-424)Ameloblastoma is the most frequent tumor of epithelial
odontogenic origin.1 Although benign, it is locally in-
vasive, with a high recurrence rate if not adequately
removed. The World Health Organization (WHO) has
recently classified it into 4 variants: solid (multicystic
ameloblastoma), extraosseous (peripheral ameloblas-
toma), desmoplastic, and unicystic.2
Adenomatoid odontogenic tumor (AOT) is a rather
uncommon tumor of odontogenic origin.3,4 Its clinical
and microscopic characteristics, biologic behavior, and
prognosis are distinct from ameloblastoma. AOT pre-
sents an indolent behavior with rare recurrences, allow-
ing a conservative treatment compared with that rec-
ommended for solid ameloblastomas.2,5
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doi:10.1016/j.tripleo.2009.03.035Matrix metalloproteinases (MMPs) are a family of
zinc- and calcium-dependent proteolytic enzymes that de-
grade the extracellular matrix (ECM) into macromole-
cules, such as collagen, gelatin, fibronectin, tenascin, and
laminin, at physiologic pH.6 More than 20 different mem-
bers are currently known and classified according to the
domain organization: collagenases (MMP-1, -8, -13, and
-18), gelatinases (MMP-2 and -9), stromelysins (MMP-3
and -10), matrilysins (MMP-7, -26, and -11), membrane-
type MMPs (MMP-14, -15, -16, -17, -24, and -25), and
other MMPs (MMP-12, -19, -20, -21, -23, -27, and -28).7
In physiologic conditions, MMPs play a central role
in the regulation of the ECM during embryonic devel-
opment and tissue remodeling.7,8 However, the degra-
dation of ECM has also been associated with diverse
pathologic processes, including tumor growth, inva-
sion, and metastasis.9,10
The matrilysins, also known as MMP-7 (matrily-
sin-1) and MMP-26 (matrilysin-2), are involved in cell
proliferation, apoptosis, invasion, and metastasis.
These matrilysins differ from other MMPs in their low
molecular weight, their lack of a C-terminal hemopexin
domain common to other MMPs, and their low expres-
sion in epithelial cells in physiologic conditions.11 Re-
search has demonstrated their expression in malignant
epithelial neoplasms12,13 and odontogenic keratocysts.14
However, no study has shown their expression in ame-
loblastoma and AOT.
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MMP-26 in ameloblastoma and AOT was examined
through immunohistochemistry, to clarify the possible
role of these matrilysins in the biologic behavior of
these tumors.
MATERIALS AND METHODS
Twenty cases of intraosseous solid ameloblastoma
(14 of the follicular and 6 of the plexiform pattern) and
10 of intraosseous AOTs were obtained from the files
of the Oral Pathology Department of the Federal Uni-
versity of Rio Grande do Norte (UFRN). Diagnoses
were confirmed by the authors through the review of
hematoxylin and eosin–stained sections, following the
WHO classification.2 The specimens, embedded in par-
affin blocks, were sliced in 3-m-thick tissue sections
and submitted to immunohistochemical examination.
The study was approved by the Research Ethics Com-
mittee at UFRN.
Immunohistochemical methods
The tissue sections were deparaffinized and im-
mersed in methanol with 0.3% hydrogen peroxide to
block endogenous peroxidase activity. Tissue sections
were then washed in phosphate-buffered saline (PBS).
The antigen retrieval, antibody dilution, and clone type
for MMP-7 and -26 are shown in Table I. After treat-
ment with normal serum, the sections were incubated in
a moist chamber with primary antibodies. The sections
were then washed twice in PBS and treated with strep-
tavidin-biotin-peroxidase complex (Dako, Glostrup, Den-
mark) at room temperature to bind the primary antibod-
ies. Peroxidase activity was visualized by immersing
tissue sections in diaminobenzidine (D5637; Sigma
Chemical, St. Louis, MO), resulting in a brown reaction
product. Finally, tissue sections were counterstained
with Mayer hematoxylin and coverslipped. Positive
controls for MMP-7 and -26 were sections of ordinary
human placenta. As negative controls, samples were
treated as above, except that the primary antibody was
replaced by a solution of bovine serum albumin in PBS.
Immunohistochemical expression evaluation and
statistical analysis
Immunohistochemical staining of MMP-7 and -26
Table I. Monoclonal antibodies used
Antibody clones Specificity Dilution
Ab-1/ID2* MMP-7 1:250
AHP756† MMP-26 1:250
*Labvision/Neomarkers, Fremont, CA.
†Serotec, Kidlington, Oxford, U.K.was evaluated using descriptive and semiquantitativeanalysis. In the latter analysis, scores from 1 to 3 were
used for the stained cells in the epithelium (Table II).
Staining in the stroma was evaluated and classified as
positive () and negative (). Parameters were inde-
pendently analyzed through light microscopy by 3 of
the authors. Then they analyzed the cases as a group to
reach a consensus.
Statistical analysis was performed using SPSS for
Windows version 15.0 (SPSS, Chicago, IL). The Mann-
Whitney test was performed in the epithelium immu-
noscores, and the chi-squared test in the stroma stain-
ing. P values of .05 were considered to indicate
statistical significance.
RESULTS
The majority of both the ameloblastomas (60%) and
the AOTs (70%) showed score 3 for MMP-7 in the
epithelium. In the ameloblastoma, staining was espe-
cially evident in central cells of epithelial nests (Fig. 1,
A and B). Stromal staining was observed in all studied
cases in fibroblasts and inflammatory and endothelial
cells (Fig. 1, E). In AOT, staining for this matrilysin
was evident in cuboidal and columnar epithelial cells
present in nests and duct-like structures (Fig. 1, C and
D). Stromal staining in AOT was shown in some fibro-
blasts and endothelial cells (Fig. 1, F).
The expression analysis of MMP-26 in the amelo-
blastoma epithelium showed that 55% of the amelo-
blastomas exhibited score 3. A variation in the location
pattern of the stained cells was observed. In the plexi-
form pattern, expression was more homogeneously dis-
tributed (Fig. 2, A), whereas in the follicular pattern
immunoreactivity was especially observed in central
cells of nests (Fig. 2, B). In the AOT epithelium, 50%
of the cases presented score 3. Staining was shown in
nests and duct-like and rosette-like structures (Fig. 2, C
Antigen retrieval Incubation
Pepsin pH 1.8, oven 37°C, 60 min Overnight (18 h)
Pepsin pH 1.8, oven 37°C, 60 min Overnight (18 h)
Table II. Immunoreactive scores used for analysis of
metalloproteinases in the epithelium
Score Immunopositive cells
1 10%
2 10%-50%
3 50%and D). In the stroma, it was observed that 65% of the
melob
fibrob
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Volume 108, Number 3 Souza Freitas et al. 419ameloblastomas and 50% of the AOTs exhibited stain-
ing for MMP-26. Stromal staining for this matrilysin
was similar for both tumors, being observed in fibro-
Fig. 1. Immunohistochemical reactivity for matrilysin-1 (me
tumors (AOTs). A, Ameloblastoma showing expression in ep
cells of epithelial nests (400). C, AOT showing expressi
epithelial cells in nests and duct-like structures (400). E, A
and endothelial cells (400). F, AOT showing expression inblasts as well as in endothelial cells (Fig. 2, E and F).Table III shows that there was no significant differ-
ence between the metalloproteinase staining medians in
the ameloblastoma epithelium and the AOTs. The same
teinase 7) in ameloblastomas and adenomatoid odontogenic
m (200). B, Ameloblastoma showing expression in central
epithelium (200). D, AOT showing strong expression in
lastoma showing expression in fibroblasts and inflammatory
lasts and endothelial cells (400).tallopro
itheliu
on inwas observed when comparing MMP-7 (P  .50) and
e-like
pressi
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420 Souza Freitas et al. September 2009MMP-26 (P  .90) staining between the 2 lesions. The
chi-squared test (Table IV) also showed no significant
Fig. 2. Immunohistochemical reactivity for matrilysin-2 (met
tumors (AOTs). A, Plexiform ameloblastoma showing expre
expression in central cells of epithelial nests (400). C, A
expression in epithelial cells in nests and duct-like and rosett
fibroblasts and endothelial cells (400). F, AOT showing exdifference in stromal MMP-26 staining between the 2lesions. Regarding MMP-7, no statistical tests were
performed, because its presence was verified in 100%
teinase 26) in ameloblastomas and adenomatoid odontogenic
in epithelium (200). B, Follicular ameloblastoma showing
owing expression in epithelium (200). D, AOT showing
structures (400). E, Ameloblastoma showing expression in
on in fibroblasts and endothelial cells (400).allopro
ssion
OT shof the samples of both lesions.
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Although ameloblastoma and AOT are classified by
WHO in the same group, formed by epithelial odonto-
genic tumors with mature fibrous stroma without odon-
togenic ectomesenchyme, these lesions present distinct
biologic behavior. Ameloblastoma is a potentially de-
structive tumor, whereas AOT presents slow, progres-
sive, and circumscribed growth.2
Various factors have been associated with the ag-
gressive behavior of ameloblastomas, such as the in-
crease in the proliferative potential,15-17 changes in the
expression of tumor suppressor genes and their protein
products,18-21 and modifications in cell cycle mecha-
nisms.22,23 Besides these, other factors have also been
investigated in an attempt of better understanding the
behavior of these tumors, such as growth factors,24
adhesion molecules,24,25 and changes in stromal com-
ponents26 and the expression of metalloproteinases and
their inhibitors, tissue inhibitor of metalloproteinases
(TIMPs).24,27-30
The MMPs play an important role in cell prolifera-
tion, angiogenesis, invasion, and metastasis in various
human malignant tumors.12,31-33 In physiologic condi-
tions, MMPs are weakly stained in the tissues, whereas
in pathological processes there is overexpression due
to the imbalance in the activity of MMPs and
TIMPs.7,10,34
Some studies have evaluated MMPs expression in
mostly distinct pathologies.35,36 Nonetheless, studies
involving cysts and odontogenic tumors are still scarce.
Among the MMPs, collagenase-1 (MMP-1) and gela-
tinases (MMP-2 and -9) seem to play an important role
in the development of these lesions, actively participat-
ing in the interactions between epithelial cells and
Table III. Immunoscores of the metalloproteinases
quartiles, and rank means
MMP Lesion n Media
MMP-7 Ameloblastoma 20 3.00
AOT 10 3.00
MMP-26 Ameloblastoma 20 3.00
AOT 10 2.50
Table IV. Immunoreactivity of the metalloprotein-
ase-26 in tumoral stroma, n (%)
MMP-26
Lesion
P valueAmeloblastoma AOT
Present 13 (65) 5 (50) .69
Absent 7 (35) 5 (50)
AOT, Adenomatoid odontogenic tumor.mesenchymal components.Previous research has confirmed MMP-1, -2, and -9
expression in ameloblastomas and odontogenic myxo-
mas, suggesting that these proteinases are involved in
the process of ECM degradation and contribute to the
local invasiveness of these tumors. The inhibition of
MMP-2 activity was also related to the decrease in local
invasiveness in ameloblastomas.27-29,37 In addition to
the high expression of MMP-2 and -9, the aggressive
behavior of these tumors has also been associated with
changes in the expression of vascular endothelial
growth factor and E-cadherin.24 Silveira et al.38 also
verified greater expression of MMP-1, -2 and -9 in the
mesenchymal cells of nonsyndrome odontogenic ker-
atocysts than in radicular, residual, and dentigerous
cysts, confirming the participation of these enzymes in
this lesion growth, as well as justifying that the first
lesions are more aggressive than the latter three. Kum-
amoto et al.27 detected strong expression of MMP-1, -2,
and -9 and TIMP-1 and -2 in mesenchymal components
of dental follicles and dental papillae and in stromal
cells of ameloblastomas. Those findings suggest that
these molecules might play a role in regulating tumor
progression in ameloblastomas as well as in regulating
developmental processes in tooth germs.
Studies involving matrilysins and odontogenic tu-
mors are even rarer. Cavalcante et al.14 evaluated the
expression of MMP-7 and -26 in syndrome and non-
syndrome odontogenic keratocysts and observed stron-
ger epithelial expression in cases associated with Gorlin
syndrome than in nonsyndrome cases, which may ex-
plain the more aggressive behavior of the keratocysts
associated with this syndrome.
In the present study, most cases of ameloblastoma
and AOT showed strong expression of MMP-7 and -26
in the epithelium as well as the stroma, which suggests
the participation of these MMPs in tissue remodeling.
Matrilysins may degrade a variety of ECM sub-
strates. MMP-7 cleaves fibronectin, gelatin, elastin,
laminin, and type IV collagen.39 Moreover, this matri-
lysin also acts in non-ECM substrates, such as tumor
necrosis factor , Fas ligand, E-cadherin, and pro–-
defensin.7 MMP-26 also shows proteolytic activity
over various components of ECM, including fibronec-
s) in tumoral epithelium, expressed with medians,
Q25 Q75 Rank mean P value
2.00 3.00 14.85 .50
2.00 3.00 16.80
2.00 3.00 15.38 .90
2.00 3.00 15.75(MMP
ntin, type IV collagen, vitronectin, gelatin, and fibrino-
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fibrinogen and inactive serpin.41,42
Because matrilysins degrade ECM proteins, their
primary function has been presumed to be tissue re-
modeling. However, their action on other substrates,
such as growth factors, growth factor protein bindings,
and adhesion molecules,7,29 may modulate cell behav-
ior,43 which might make matrilysins to play a central role
in tumor invasion and metastasis.44 Additionally, MMP-7
activates latent forms of other MMPs (proMMP-1, -2, and
-9) and MMP-26 activates MMP-9.39,45 Because gelati-
nases are involved in tumor invasion processes and me-
tastasis,9,24,28-30,33,46,47 the present findings indirectly sug-
gest the participation of MMP-7 and -26 in invasive
processes in ameloblastomas, because their strong immu-
noexpression can be correlated with the activation of
MMPs -2 and -9.
Some MMPs are expressed by tumor and host
cells.48 Expression of MMP-7 has been described in
epithelial cells, myofibroblasts, macrophages, and en-
dothelial cells.48,49 Cloned MMP-26 was expressed by
macrophages and fibroblasts in vivo and in culture,
suggesting that this MMP may contribute to both phys-
iologic processes of tissue remodeling and various be-
nign skin disorders.50 MMP-26 expression was shown
in normal tissues of endometrium, placenta, and kid-
ney.45 Furthermore, up-regulation of these matrilysins
was associated with tumors of epithelial origin.31,44 In
the present study, expression of these matrilysins was
shown in both tumor and stromal cells. MMP-7 was
evident in epithelial cells, fibroblasts, and endothelial
cells of both tumors and in inflammatory cells of the
ameloblastomas. And MMP-26 was observed in epithe-
lial cells, fibroblasts, and endothelial cells in both
ameloblastomas and AOTs.
Even though there was neither association between
MMP staining and the studied lesions nor significant
difference between medians of MMPs in the epithe-
lium, our results, when analyzed as a whole, suggest
that stromal cells from both studied tumors are capable
of producing MMPs with more or less efficiency de-
pending to the studied MMP. That suggests that these
enzymes can potentialize the action of epithelium-pro-
duced MMPs.
The literature agrees with the role of the stromal
microenvironment in tumoral progression, showing ev-
idence of cooperation or synergy between neoplasic
cells and stromal fibroblasts in MMP production.48,51
According to Lynch and Matrisian,52 MMPs of either
tumoral or stromal origin may process cell surface
molecules, proteins, or growth factors and cytokines
stored in the EMC, causing changes in the microenvi-
ronment and thereby favoring tumor growth, migration,
invasion, angiogenesis, and selection of cell clonesresistant to apoptosis. Accordingly, those authors be-
lieve that MMPs can be used as a means of communi-
cation between tumor and stromal cells.
In addition, changes in stromal components may
occur due to an imbalance in cytokines, resulting in
changes that may ease the transdifferentiation of fibro-
blasts into myofibroblasts (MFs). MFs are specialized
stromal cells that display a hybrid phenotype between
fibroblasts and smooth muscle cells.53 Earlier studies
have identified the presence of these cells in neo-
plasms,53,54 including odontogenic tumors,55 relating
them to the biologic behavior of these lesions. MFs
were identified in ameloblastomas,55-57 and a high rate
of these cells was observed in more aggressive tumors,
such as solid ameloblastomas and odontogenic kerato-
cysts.55 MFs may produce high levels of MMP-2, and
the intensive presence of these cells and gelatinases in
solid ameloblastomas has been associated with disrup-
tion of cortical bone and increased aggressiveness of
these tumours.26
From our findings, it is plausible to conclude that the
expression of these matrilysins suggests their participa-
tion in the process of tissue remodeling and ameloblas-
toma and AOT growth, but this expression does not
relate to the their distinct patterns of aggressiveness.
However, these matrilysins may indirectly act through
the activation of other MMPs associated with changes
in the stromal components, which could contribute to
the greater aggressiveness of ameloblastomas. We
therefore believe that further studies investigating the
expression of MMPs and their relationship to stromal
components, as well as the use of other techniques,
such as zymography, should be undertaken in an at-
tempt to better understand the role and influence of
these enzymes in the behavior of the studied tumors.
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